<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498979</url>
  </required_header>
  <id_info>
    <org_study_id>CASE3Y06</org_study_id>
    <nct_id>NCT00498979</nct_id>
  </id_info>
  <brief_title>Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers</brief_title>
  <official_title>Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor&#xD;
      cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as&#xD;
      cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving sodium&#xD;
      stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sodium&#xD;
      stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and&#xD;
      dacarbazine in treating patients with advanced melanoma or other cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the safety of the combination of sodium stibogluconate and interferon&#xD;
           alfa-2b with chemotherapy.&#xD;
&#xD;
        -  To confirm the activity of sodium stibogluconate in augmenting cytokine effects.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To quantify the effects of sodium stibogluconate on interferon alfa-2b induced gene&#xD;
           modulation and signal transduction pathways by measuring the serum soluble gene&#xD;
           products.&#xD;
&#xD;
        -  To define the effectiveness of sodium stibogluconate in inhibiting the protein tyrosine&#xD;
           phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes of patients&#xD;
           receiving sodium stibogluconate in combination with interferon alfa-2b.&#xD;
&#xD;
        -  To define the pharmacokinetics of sodium stibogluconate in serum at escalating doses.&#xD;
&#xD;
        -  To assess clinical response to the combination of sodium stibogluconate and interferon&#xD;
           alfa-2b as priming for combination chemotherapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Course 1: Patients receive sodium stibogluconate IV over 15 minutes on day 1 and days&#xD;
           15-18; interferon alfa-2b subcutaneously (SC) on days 8-12 and 15-18; cisplatin IV over&#xD;
           30-60 minutes and vinblastine IV on days 19 and 20; and dacarbazine. After a 2-week rest&#xD;
           period, patients proceed to course 2.&#xD;
&#xD;
        -  Course 2 and all subsequent courses: Patients receive sodium stibogluconate IV over 15&#xD;
           minutes and interferon alfa-2b SC on days 1-4; cisplatin IV over 30-60 minutes and&#xD;
           vinblastine IV on days 5 and 6; dacarbazine. Courses repeat every 4 weeks in the absence&#xD;
           of disease progression or unacceptable toxicity.* NOTE: *Patients with stage IV disease&#xD;
           who have no evidence of disease [NED} receive only 4 courses of therapy.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of sodium stibogluconate until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which&#xD;
      dose-limiting toxicity occurs (i.e., no more than 1 patient at a given dose experiences DLT).&#xD;
&#xD;
      Patients undergo blood sample collection periodically for immunological and pharmacokinetic&#xD;
      studies. Samples are analyzed for serum soluble gene products and protein tyrosine&#xD;
      phosphatase inhibition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of sodium stibogluconate in serum at escalating doses</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant interferon alfa-2b</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
    <description>recombinant interferon alfa-2b</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>IFN 2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>recombinant interferon alfa-2b</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium stibogluconate</intervention_name>
    <description>sodium stibogluconate</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>dacarbazine</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>vinblastine</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>VBL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma or other malignancies&#xD;
&#xD;
               -  Must be refractory or resistant to established treatments OR have metastatic&#xD;
                  disease for which no effective therapy has been established&#xD;
&#xD;
               -  Gliomas or controlled CNS metastasis allowed&#xD;
&#xD;
                    -  A CT scan or MRI must confirm stable brain metastases within 28 days of&#xD;
                       study entry&#xD;
&#xD;
                    -  Patients with primary CNS malignancies refractory to other therapies are&#xD;
                       eligible&#xD;
&#xD;
          -  Malignancy potentially responsive to sodium stibogluconate and/or interferon alfa-2b&#xD;
             and combination chemotherapy&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease&#xD;
&#xD;
               -  Evaluable disease can include clinically or radiographically nonmeasurable tumor,&#xD;
                  specific tumor markers, or stage IV patients with no evidence of disease (NED)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               -  ECOG performance status 0-2&#xD;
&#xD;
               -  Granulocytes &gt; 1,500/μl&#xD;
&#xD;
               -  Platelets &gt; 100,000/μl&#xD;
&#xD;
               -  Creatinine &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               -  AST and ALT &lt; 1.5 x ULN (unless due to hepatic metastases)&#xD;
&#xD;
               -  Potassium ≤ 5.0 mmol/L&#xD;
&#xD;
               -  Magnesium ≤ 2.4 mg/dL&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 cc/min&#xD;
&#xD;
               -  Ejection fraction ≥ 50%&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  Pregnant or lactating women and fertile women or men unless surgically sterile or&#xD;
                  using effective contraception&#xD;
&#xD;
                    -  All female patients of childbearing potential or less than 1 year&#xD;
                       postmenopausal must have a negative β-HCG pregnancy test at baseline and&#xD;
                       practice a medically acceptable method of birth control (i.e., oral&#xD;
                       contraceptives for at least 3 months, implantation of an intrauterine device&#xD;
                       for at least 2 months, or barrier methods [e.g., vaginal diaphragm, vaginal&#xD;
                       sponge, or condom with spermicidal jelly]) during and for 3 months after&#xD;
                       study initiation&#xD;
&#xD;
               -  History of atrial fibrillation, flutter, or other serious arrhythmia (excluding&#xD;
                  asymptomatic atrial or ventricular premature complexes) in the past 24 months&#xD;
&#xD;
               -  History of congestive heart failure currently requiring treatment; angina&#xD;
                  pectoris; or other severe cardiovascular disease (i.e., New York Heart&#xD;
                  Association class III or IV heart disease)&#xD;
&#xD;
               -  Baseline ECG abnormalities suggestive of cardiac conduction delay (i.e., first&#xD;
                  degree or greater atrio-ventricular block and/or complete or incomplete [QRS &gt;&#xD;
                  120 ms] bundle branch block)&#xD;
&#xD;
               -  Baseline ECG abnormalities suggestive of repolarization abnormalities (i.e., QTc&#xD;
                  ≥ 0.48 sec)&#xD;
&#xD;
               -  Culture positive acute infections requiring antibiotics within the past 14 days&#xD;
&#xD;
                    -  Patients on long term suppressive antibiotic therapies are eligible&#xD;
&#xD;
               -  Known to be positive for HBsAg&#xD;
&#xD;
               -  Patients judged to not be psychologically prepared to understand informed consent&#xD;
                  or comply with an investigational study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               -  Prior interferon therapy is allowed if administered ≥ 4 months ago&#xD;
&#xD;
               -  At least 3 weeks since prior major surgery, radiation therapy, or chemotherapy&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  No prior treatment with interferon, sodium stibogluconate, cisplatin,&#xD;
                  vinblastine, or dacarbazine, except if given in an adjuvant setting&#xD;
&#xD;
               -  Patients with a prior history of solid organ allografts or allogeneic bone marrow&#xD;
                  transplant&#xD;
&#xD;
               -  Patients taking the following medications will not be eligible:&#xD;
&#xD;
                    -  Amiodarone (Cordarone)&#xD;
&#xD;
                    -  Disopyramide (Norpace)&#xD;
&#xD;
                    -  Dofetilide (Tikosyn)&#xD;
&#xD;
                    -  Procainamide (Procanbid or Pronestyl)&#xD;
&#xD;
                    -  Quinidine (Quinaglute)&#xD;
&#xD;
                    -  Sotalol (Betapace)&#xD;
&#xD;
                    -  Erythromycin&#xD;
&#xD;
                    -  Azithromycin (Z-pack)&#xD;
&#xD;
                    -  Clarithromycin (Biaxin)&#xD;
&#xD;
                    -  Pentamidine (Pentacarinat)&#xD;
&#xD;
                    -  Trimethoprim-sulfamethoxazole (Bactrim)&#xD;
&#xD;
                    -  Bepridil (Vascor)&#xD;
&#xD;
                    -  Phenothiazines (e.g., prochlorperazine [Compazine], promethazine&#xD;
                       [Phenergan], or chlorpromazine [Thorazine])&#xD;
&#xD;
                    -  Butyrophenones (e.g., Haloperidol [Haldol])&#xD;
&#xD;
                    -  Risperidone (Risperdal)&#xD;
&#xD;
                    -  Any other antipsychotic medication&#xD;
&#xD;
                    -  Tricyclic or tetracyclic antidepressants (e.g., imipramine [Tofranil],&#xD;
                       amitriptyline [Elavil], desipramine [Norpramin], or nortriptyline [Pamelor])&#xD;
&#xD;
                    -  Monoamine oxidase inhibitors&#xD;
&#xD;
                    -  High-dose methadone&#xD;
&#xD;
                    -  Arsenic trioxide&#xD;
&#xD;
                    -  Dolasetron (Anzemet)&#xD;
&#xD;
                    -  Any herbal preparations&#xD;
&#xD;
               -  Use of daily glucocorticoids except for physiological replacement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>mixed gliomas</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

